Contractile effects of angiotensinogen and its multiple metabolization pathways on vessel walls.
The contractile effects of angiotensinogen (Aogen) and its metabolization pathways were studied on rat renal vein (RRV), rat pulmonary artery (RPA) and human umbilical vein (HUV) rings. Experiments were made in the presence or in the absence of pepstatin A (a renin inhibitor, 10 microM), captopril (an ACE inhibitor, 10 microM), chymostatin (a chymase inhibitor, 10 microM), amastatin (an aminopeptidase-A and -M inhibitor) or losartan (a specific AT1 blocker, 10 microM). On all rings, Aogen-induced contractions were reduced by pepstatin A or captopril, amplified by amastatin and blocked by losartan. Chymostatin had a stronger inhibitory effect than captopril on HUV and simultaneous administering of chymostatin and captopril prevented Aogen contractile effects on HUV. It is suggested that all studied vessels possess a local renin-angiotensin system and possibility of angiotensin II production within the vessel walls using various and species-dependent enzymatic pathways.
Cernucan
Dana Luiza
DL
Gr. T. Popa University of Medicine and Pharmacy Iaşi, School of Medicine, Physiology Department.
Gurzu
B
B
Slătineanu
S
S
Dumitriu
Irina Luciana
IL
Slătineanu
Simona Mihaela
SM
Costuleanu
M
M
Petrescu
G
G
D000808:Angiotensinogen / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism; D011651:Pulmonary Artery / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D012082:Renal Veins / Q000187:drug effects*; D014471:Umbilical Veins / Q000187:drug effects*
D000808:Angiotensinogen